



Original research

Does helicobacter pylori infection have influence on outcome of laparoscopic sleeve gastrectomy for morbid obesity?



Gianluca Rossetti ^{a, *}, Francesco Moccia ^a, Teresa Marra ^a, Mattia Buonomo ^a, Beniamino Pascotto ^a, Angelo Pezzullo ^a, Vincenzo Napolitano ^a, Pietro Schettino ^a, Manuela Avellino ^a, Giovanni Conzo ^a, Bruno Amato ^b, Giovanni Docimo ^c, Salvatore Tolone ^c, Gianmattia Del Genio ^c, Ludovico Docimo ^c, Landino Fei ^a

^a Department of Anaesthesiological, Surgical and Emergency Sciences, Division of Digestive Surgery, School of Medicine, Second University of Naples, Via Pansini Naples 5, 80131 Naples, Italy

^b Department of Clinical Medicine and Surgery, School of Medicine, University of Naples Federico II, Italy

^c Division of General and Bariatric Surgery, School of Medicine, Second University of Naples, Italy

ARTICLE INFO

Article history:

Received 23 March 2014

Accepted 3 May 2014

Available online 23 May 2014

Keywords:

Helicobacter pylori
Morbid obesity
Sleeve gastrectomy
Laparoscopy

ABSTRACT

Introduction: Among the surgical procedures for treatment of morbid obesity, laparoscopic sleeve gastrectomy has known widespread diffusion in the last years, although it is not free from significant morbidity rates. Aim of this work is to evaluate the incidence of *Helicobacter pylori* (HP) infection on the postoperative outcome of patients undergoing laparoscopic sleeve gastrectomy.

Methods: Between January 2008 and December 2013, 184 patients (65 males, 119 females), mean age 35.8 ± 5.7 years, affected with morbid obesity, mean BMI 46.6 ± 6.7 , underwent laparoscopic sleeve gastrectomy. All the specimens at the end of the operation were analysed by the same pathologist. Histological grading was based on the Sidney classification.

Results: Seventy-two of the patients (39.1%) were HP positive, while 112 (60.9%) were negative. No significant differences were observed between the HP+ and HP- group in terms of age, sex, weight, BMI, incidence of comorbidities and duration of follow-up. All the operations were completed via laparoscopic approach. No mortality was observed. Postoperative complications occurred in 5 patients (2.7%): three leaks (1.6%), all in the HP- group and two bleedings (1.1%), one in the HP+ and one in the HP- group. In two cases a reintervention was necessary. No significant differences were observed in the morbidity rates between the two groups. Overall mean excess weight loss at 6 months, 12 months and 24 months was respectively $47.4 \pm 11.3\%$, $61.1 \pm 12.4\%$ and $68.4 \pm 13.5\%$, with no significant differences between the HP+ and HP- groups.

Conclusions: HP infection seems not to influence postoperative outcome of patients operated of laparoscopic sleeve gastrectomy.

© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Helicobacter pylori, for the first time described by Warren and Marshall in 1984 [1], has been object of many trials who clarified its role in the pathogenesis of peptic ulcer disease and gastric cancer, while contradictory results emerged from different epidemiologic studies who tried to evaluate its correlation with morbid obesity [2–6]. In the last 20 years laparoscopic bariatric surgery has known widespread diffusion for its excellent results in terms of excess weight loss and resolution of comorbidities [7,8]. Among the

different surgical procedures, laparoscopic sleeve gastrectomy (LSG) is becoming a popular restrictive procedure as it is effective in achieving 60–70% excess weight loss at a medium term follow up [9,10], although it is not free from significant complications rates [11–13]. Aim of this work is to evaluate the role of *Helicobacter pylori* (HP) infection on the postoperative outcome of patients undergoing laparoscopic sleeve gastrectomy.

2. Methods

Between January 2008 and December 2013, patients affected with morbid obesity came to our observation and were included in the study. Inclusion criteria were a body mass index greater than

* Corresponding author.

E-mail address: gianlucarossetti@yahoo.it (G. Rossetti).

40 kg/m² or greater than 35 kg/m² associated with relevant comorbidities, failed medical treatment of >5 years, and age 18–60 years. Exclusion criteria were contraindications to laparoscopic surgery, a second bariatric operation, previous gastric surgery, giant hiatal hernia, severe gastroesophageal reflux disease, pregnancy, psychiatric disease, and BMI >60 kg/m². Patients were addressed to LSG after a multidisciplinary team evaluation including a surgical, psychiatric, nutritional and endocrinological visit. Preoperative examinations included complete blood laboratory exams, electrocardiogram and cardiologic visit, chest x-ray and pulmonary function test, upper endoscopy and abdominal ultrasound. Informed consent was obtained before the operation. Primary end-point were early and late complications, while secondary end-point was excess weight loss (EWL). Early complications were those occurring during the first 30 postoperative days, and late complications were later on.

3. Surgical technique

As previously described [13], the operation was conducted via laparoscopic approach. After pneumoperitoneum induction at a 15 mmHg value by a Veress needle, five trocars were introduced. Dissection of gastric greater curvature started at 3 cm from the pylorus and was conducted upwards until the angle of His by means of Ligasure (Covidien, Mansfield, MA). Resection of the stomach was performed by Echelon 60 Endopath (Ethicon Endo-Surgery, Cincinnati, OH) with green and gold cartridges, under a 36-Fr calibration bougie. Once the gastric partition had been completed, an upper endoscopy was performed to check the integrity of the suture line. Resected stomach was extracted from the abdominal cavity through a dilated 12-mm trocar incision in a specimen bag. At the end of operation, a drain was placed alongside the staple line: it was removed generally on 5th postoperative day after performing an upper GI X-ray. The patients were discharged home on the 6th postoperative day with prescription of a 40 mg per day oral PPI therapy for six months. Liquid diet started on 6th postoperative day and was allowed for 10–15 days under strict nutritionist surveillance.

4. Specimens evaluation

All the sleeve gastrectomy specimens were analysed by the same pathologist who was unaware of clinical information. Biopsy specimens were fixed in 10% formalin and embedded in paraffin. The sections were subsequently stained with ematoxylin and eosin. Giemsa staining was used to detect the existence of HP. Histological grading was based on the Sidney classification [14]. Accordingly, the following histopathologic variables were examined on each case: *Helicobacter pylori* density, polymorphonuclear neutrophil activity, degree of chronic inflammation, degree of glandular atrophy, presence of intestinal metaplasia. Each variable was graded as

mild, moderate or severe using Dixon et al. visual analogue scale [14]. *Helicobacter pylori* density was grade as none, mild when few microorganism were present, moderate when bacteria were present in separate foci and severe when near complete or complete surface layering with *Helicobacter pylori* was observed. Polymorphonuclear neutrophil activity was classified as none, mild when up to two crypts were involved per biopsy, moderate when up to 50% of crypts were involved and severe when more than 50% of crypts were affected. Chronic inflammation was defined as gastric mucosa infiltration by both lymphocytes and plasma cells. It was graded as none, mild when chronic inflammatory cells were scattered, moderate when chronic inflammatory cells infiltrate were diffuse and severe when chronic inflammatory cells were diffuse and dense separating the gastric glands. Glandular atrophy was scored as none, mild, moderate and severe using the visual analogue score. Intestinal metaplasia was graded as none, mild when one focus-up to four crypts- was replaced by intestinal type epithelium, moderate when multiple foci were affected comprising less than 50% of gastric epithelium, and severe when more than 50% of gastric epithelium was replaced by intestinal metaplasia.

5. Statistical analysis

Continuous demographic and anthropometric variables were expressed as mean \pm standard deviation. Correlation between ordinal or continuous variables was performed using Spearman rank correlation test. Comparisons between groups were made using the Student *t*-test for continuous variables. The Pearson χ^2 contingency test was used to test the significance of differences between proportions and categorical variables. Histologic score of gastritis was treated as ordinal variables. Spearman rank correlations were used to test the correlation between histologic score of gastritis and preoperative body weight data as well as percentage of excess weight loss at different follow-up intervals. Independent predictors of good and poor results were identified by multivariate binary logistic regression. All analyses were two-tailed. A *p*-value <0.05 was considered statistically significant. The SPSS statistical software (SPSS, Inc., Chicago, IL) was used for statistical analysis.

6. Results

A total of 184 patients (65 males, 119 females) were enrolled. Their mean age was 35.8 \pm 5.7 years (range 19–59), mean BMI 46.6 \pm 6.7 (range 37.5–59.1). Seventy-two of the patients (39.1%) were HP positive, while 112 were negative (60.9%). Mean follow-up was 27.6 \pm 6.8 months (range 3–74). Demographic and preoperative data are summarized in Table 1. No significant differences were observed between the HP+ and HP- group in terms of age, sex, weight, BMI, incidence of comorbidities and duration of follow-up. All the interventions were completed via laparoscopic approach. No intraoperative complications occurred. No mortality was observed

Table 1
Demographic and anthropometric data.

	All patients (n = 184)	HP+ (n = 72) (39.1%)	HP- (n = 112) (60.9%)	P value
Sex	65M (35.3%) 119F (64.7%)	21M (29.2%) 51F (70.8%)	44M (39.3%) 68F (60.7%)	0.235
Age (years) (range)	35.8 \pm 5.7 (19–59)	32.4 \pm 4.5 (19–57)	37.3 \pm 5.2 (20–59)	0.123
Weight (Kg) (range)	130.8 \pm 19.3 (90–180)	124.5 \pm 17.2 (90–165)	132.6 \pm 12.3 (95–180)	0.224
BMI (Kg/m ²) (range)	46.6 \pm 6.7 (37.5–59.1)	44.4 \pm 5.2 (38.6–59.1)	47.2 \pm 4.3 (37.5–58.7)	0.346
Hypertension	57 (31.0%)	20 (27.8%)	37 (33.0%)	0.233
Diabetes	48 (26.1%)	19 (26.4%)	29 (25.9%)	0.678
Sleep apnea	18 (9.8%)	6 (8.3%)	12 (10.7%)	0.455
Follow-up (months) (range)	27.6 \pm 6.8 (3–74)	26.5 \pm 5.4 (3–73)	28.1 \pm 4.3 (4–74)	0.787

Table 2
Postoperative results.

	All patients (n = 184)	HP+ (n = 72) (39.1%)	HP- (n = 112) (60.9%)	P Value
Intraoperative blood loss (ml) (range)	45.3 ± 15.4 (30–150)	42.1 ± 12.3 (30–120)	46.4 ± 14.1 (40–150)	0.342
Operative time (min) (range)	64.4 ± 12.6 (55–125)	63.2 ± 11.4 (60–125)	65.6 ± 14.1 (55–120)	0.577
Overall morbidity	5 (2.7%)	1 (1.4%)	4 (3.6%)	0.09
Leak	3 (1.6%)	0	3 (2.7%)	0.067
Bleeding	2 (1.1%)	1 (1.4%)	1 (0.9%)	0.124
Hospital stay	6.4 ± 3.3 (5–25)	5.3 ± 2.4 (5–13)	6.5 ± 2.2 (5–25)	0.078
EWL 6 months (%)	47.4 ± 11.3	46.3 ± 12.9	48.5 ± 11.7	0.355
EWL 12 months (%)	61.1 ± 12.4	63.5 ± 14.2	60.1 ± 11.4	0.246
EWL 24 months (%)	68.4 ± 13.5	66.4 ± 14.1	69.3 ± 13.3	0.112

in both groups. Mean operative time was 64.4 ± 12.6 min (range 55–125) while mean hospital stay was 6.4 ± 3.3 days (range 5–25) with no significant differences between the two groups (Table 2). Overall morbidity was as following: three leaks (1.6%) occurred, all in the HP- group and two bleedings (1.1%), one in the HP+ and one in the HP- group. In two patients a reintervention was necessary, in one case for the treatment of a leak occurred on the 3rd postoperative day, repaired via laparoscopic approach by means of direct suture and abdominal cavity drainage and in another case for an emergency splenectomy for massive bleeding. In all the other cases a conservative treatment was successful and no reoperation was necessary. No significant differences were observed in the morbidity rates between the two groups (Table 2). Overall mean EWL at 6 months, 12 months and 24 months was respectively $47.4 \pm 11.3\%$, $61.1 \pm 12.4\%$ and $68.4 \pm 13.5\%$, with no significant differences between the HP+ and HP- groups (Table 2).

7. Discussion

While different trials have investigated the correlation between HP infection and morbid obesity with contradictory results [2–6], a limited number of articles have been published dealing with the influence of HP on postoperative outcome of laparoscopic bariatric surgery. Wang et al. [15] investigated the role of HP on the outcome of laparoscopic vertical banded gastroplasty: they observed no correlation with morbidity incidence, while less excess weight loss at 24 and 48 months was achieved in patients HP+. Hartin Jr. et al. [16] evaluated a series of patients operated of laparoscopic gastric bypass: while no postoperative complication arised among the patients tested and treated for HP in the preoperative assessment, a perforation of gastrojejunal anastomosis occurred in 5% of patients not tested. They concluded that preoperative HP screening should be routinely performed in order to decrease the rate of postoperative complications. This was the only study finding a positive correlation between HP infection and postoperative complications in bariatric surgery. Recently, other two studies [17,18] investigated the role of HP on postoperative outcome of sleeve gastrectomy: both concluded that HP infection has no impact on postoperative morbidity rates. Even, another trial documented that LSG can bring, as a consequence, to eradication of *Helicobacter pylori* infection: Keren et al. [19], on a group of 40 patients operated of LSG, observed HP infection in 17 cases (42.5%) in excluded stomach. At a 3-months follow-up, only three out of them (17.6%) were tested positive for HP at urea breath test. Our results support the evidences emerged from the literature as no correlation was documented between HP and occurrence of postoperative complications: even, gastric leaks occurred only in patients HP- (3/112, 2.7% vs 0% in HP+ group) ($p = 0.067$) (NS). Furthermore, at our knowledge, our trial is the first one to evaluate not only the impact of HP infection on postoperative complications, but even on EWL of LSG at a medium term follow-up: as it has been evidenced in

Table 2, no differences were observed in terms of EWL between HP+ and HP- groups at 6, 12 and 24 months follow-up. In conclusion, in our opinion, while routine upper endoscopy should always be performed in the preoperative assessment of patients candidate to bariatric surgery [20,21], eradication of HP infection before undergoing intervention is not mandatory as it seems not to have influence on outcome of patients operated for morbid obesity.

Ethical approval

None.

Conflict of interest statement

All the Authors declare no conflict of interest.

Funding

None.

Author contribution

Gianluca Rossetti: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Francesco Moccia: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Teresa Marra: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Mattia Buonomo: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Beniamino Pascotto: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Angelo Pezzullo: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Vincenzo Napolitano: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Pietro Schettino: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Manuela Avellino: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Giovanni Conzo: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Bruno Amato: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data.

Giovanni Docimo: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Salvatore Tolone: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Gianmattia Del Genio: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Ludovico Docimo: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

Landino Fei: Participated substantially in conception, design, and execution of the study and in the analysis and interpretation of data; also participated substantially in the drafting and editing of the manuscript.

References

- [1] B.J. Marshall, J.R. Warren, Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration, *Lancet* 1 (8390) (1984 Jun 16) 1311–1315.
- [2] I. Cho, M.J. Blaser, F. François, et al., *Helicobacter pylori* and overweight status in the United States: data from the third National Health and Nutrition Examination Survey, *Am. J. Epidemiol.* 162 (2005) 579–584.
- [3] G.N. Ioannou, N.S. Weiss, D.J. Kearney, Is *Helicobacter pylori* seropositivity related to body mass index in the United States? *Aliment. Pharmacol. Ther.* 21 (2005) 765–772.
- [4] M.S. Wu, W.J. Lee, H.H. Wang, S.P. Huang, J.T. Lin, A case-control study of association of *Helicobacter pylori* infection with morbid obesity in Taiwan, *Arch. Intern. Med.* 165 (2005) 1552–1555.
- [5] T. Erim, M.R. Cruz-Correa, S. Szomstein, E. Velis, R. Rosenthal, Prevalence of *Helicobacter pylori* seropositivity among patients undergoing bariatric surgery: a preliminary study, *World J. Surg.* 32 (2008) 2021–2025.
- [6] E. Arslan, H. Atilgan, I. Yavasoglu, The prevalence of *Helicobacter pylori* in obese subjects, *Eur. J. Intern. Med.* 20 (2009) 695–697.
- [7] W.J. Pories, M.S. Swanson, K.G. MacDonald, et al., Who would have thought it? an operation proves to be the most effective therapy for adult-onset diabetes mellitus, *Ann. Surg.* 222 (1995) 339–350.
- [8] P.R. Schauer, S.R. Kashyap, K. Wolski, et al., Bariatric surgery versus intensive medical therapy in obese patients with diabetes, *N Engl. J. Med.* 366 (2012) 1567–1576.
- [9] N.T. Nguyen, B. Nguyen, A. Gebhart, S. Hohmann, Changes in the make-up of bariatric surgery: a national increase in use of laparoscopic sleeve gastrectomy, *J. Am. Coll. Surg.* 216 (2013) 252–257.
- [10] A.M. Carlin, T.M. Zeni, W.J. English, et al., The comparative effectiveness of sleeve gastrectomy, gastric bypass and adjustable gastric banding procedures for the treatment of morbid obesity, *Ann. Surg.* 257 (2013) 791–797.
- [11] X. Shi, S. Karmali, A.M. Sharma, D.W. Birch, A review of laparoscopic sleeve gastrectomy for morbid obesity, *Obes. Surg.* 20 (2010) 1171–1177.
- [12] M. Parikh, R. Issa, A. McCrillis, J.K. Saunders, A. Ude-Welcome, M. Gagner, Surgical strategies that may decrease leak after laparoscopic sleeve gastrectomy: a systematic review and meta-analysis of 9991 cases, *Ann. Surg.* 257 (2013) 231–237.
- [13] G. Rossetti, L. Fei, L. Docimo, et al., Is nasogastric decompression useful in prevention of leaks after laparoscopic sleeve gastrectomy? A randomized trial, *J. Invest. Surg.* (2014 Jan 29) (Epub ahead of print), PMID 24476003.
- [14] F. Dixon, R.M. Genta, J.H. Yardley, P. Correa, Classification and grading of gastritis: the updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994, *Am. J. Surg. Pathol.* 20 (1996) 1161–1181.
- [15] H.H. Wang, W.J. Lee, P. Liew, et al., The influence of *Helicobacter pylori* infection and corpus gastritis on the postoperative outcomes of laparoscopic vertical banded gastroplasty, *Obes. Surg.* 16 (2006) 297–307.
- [16] C.W. Hartin Jr., D.S. ReMine, T.A. Lucktong, Preoperative bariatric screening and treatment of *Helicobacter pylori*, *Surg. Endosc.* 23 (2009) 2531–2534.
- [17] A. Albawardi, S. Almarzooqi, F.C. Torab, *Helicobacter pylori* in sleeve gastrectomies: prevalence and rate of complications, *Int. J. Clin. Exp. Med.* 6 (2013) 140–143.
- [18] S. Almazeedi, S. Al-Sabah, D. Alshammari, et al., The impact of *Helicobacter pylori* on the complications of laparoscopic sleeve gastrectomy, *Obes. Surg.* 24 (2014) 412–415.
- [19] D. Keren, I. Matter, T. Rainis, O. Goldstein, E. Stermer, A. Lavy, Sleeve gastrectomy leads to *Helicobacter pylori* eradication, *Obes. Surg.* 19 (2009) 751–756.
- [20] R. Munoz, L. Ibanez, J. Salinas, et al., Importance of routine preoperative upper GI endoscopy: why all patients should be evaluated? *Obes. Surg.* 19 (2009) 427–431.
- [21] M.A. Kuper, T. Kratt, K.M. Kramer, et al., Effort, safety and findings of routine preoperative endoscopic evaluation of morbidly obese patients undergoing bariatric surgery, *Surg. Endosc.* 24 (2010) 1996–2001.